company background image
HARP logo

Harpoon Therapeutics NasdaqCM:HARP 株式レポート

最終価格

US$23.01

時価総額

US$492.3m

7D

0.2%

1Y

243.4%

更新

11 Mar, 2024

データ

会社財務 +

Harpoon Therapeutics, Inc.

NasdaqCM:HARP 株式レポート

時価総額:US$492.3m

HARP 株式概要

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases in the United States.

HARP ファンダメンタル分析
スノーフレーク・スコア
評価1/6
将来の成長2/6
過去の実績0/6
財務の健全性5/6
配当金0/6

Harpoon Therapeutics, Inc. 競合他社

価格と性能

の歴代最高値、変動、値下がりまとめHarpoon Therapeutics
過去の株価
現在の株価US$23.01
52週高値US$23.21
52週安値US$3.11
ベータ2.1
11ヶ月の変化2.49%
3ヶ月変化162.97%
1年変化243.43%
33年間の変化-88.71%
5年間の変化-81.26%
IPOからの変化-82.96%

最新ニュース

Improved Revenues Required Before Harpoon Therapeutics, Inc. (NASDAQ:HARP) Stock's 97% Jump Looks Justified

Jan 30
Improved Revenues Required Before Harpoon Therapeutics, Inc. (NASDAQ:HARP) Stock's 97% Jump Looks Justified

Recent updates

Improved Revenues Required Before Harpoon Therapeutics, Inc. (NASDAQ:HARP) Stock's 97% Jump Looks Justified

Jan 30
Improved Revenues Required Before Harpoon Therapeutics, Inc. (NASDAQ:HARP) Stock's 97% Jump Looks Justified

Harpoon Therapeutics, Inc. (NASDAQ:HARP) Looks Inexpensive After Falling 55% But Perhaps Not Attractive Enough

Oct 01
Harpoon Therapeutics, Inc. (NASDAQ:HARP) Looks Inexpensive After Falling 55% But Perhaps Not Attractive Enough

Analysts Just Made A Notable Upgrade To Their Harpoon Therapeutics, Inc. (NASDAQ:HARP) Forecasts

Aug 14
Analysts Just Made A Notable Upgrade To Their Harpoon Therapeutics, Inc. (NASDAQ:HARP) Forecasts

Forecast: Analysts Think Harpoon Therapeutics, Inc.'s (NASDAQ:HARP) Business Prospects Have Improved Drastically

May 28
Forecast: Analysts Think Harpoon Therapeutics, Inc.'s (NASDAQ:HARP) Business Prospects Have Improved Drastically

Harpoon Therapeutics (NASDAQ:HARP) Will Have To Spend Its Cash Wisely

Mar 11
Harpoon Therapeutics (NASDAQ:HARP) Will Have To Spend Its Cash Wisely

Harpoon Therapeutics appoints Luke Walker as CMO

Oct 04

Harpoon Therapeutics: A Well Undervalued Tri-Specific Oncology Player

Sep 01

Here's Why We're A Bit Worried About Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Situation

Jul 30
Here's Why We're A Bit Worried About Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Situation

Harpoon Therapeutics: A T-Cell Engager Platform And A Negative Enterprise Value Makes It A Candidate For My 'Bio Boom' Portfolio

Jul 07

Is Harpoon Therapeutics (NASDAQ:HARP) In A Good Position To Invest In Growth?

Mar 08
Is Harpoon Therapeutics (NASDAQ:HARP) In A Good Position To Invest In Growth?

We're Keeping An Eye On Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Rate

Nov 30
We're Keeping An Eye On Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Rate

Harpoon Therapeutics: A First Look

Sep 16

Harpoon shares slide after early-stage prostate cancer study data fails to impress

Jun 04

株主還元

HARPUS BiotechsUS 市場
7D0.2%-0.7%-1.6%
1Y243.4%19.8%30.8%

業界別リターン: HARP exceeded the US Biotechs industry which returned 16% over the past year.

リターン対市場: HARP exceeded the US Market which returned 31% over the past year.

価格変動

Is HARP's price volatile compared to industry and market?
HARP volatility
HARP Average Weekly Movement32.6%
Biotechs Industry Average Movement9.6%
Market Average Movement6.0%
10% most volatile stocks in US Market14.9%
10% least volatile stocks in US Market2.9%

安定した株価: HARP's share price has been volatile over the past 3 months.

時間の経過による変動: HARP's weekly volatility has increased from 21% to 33% over the past year.

会社概要

設立従業員CEO(最高経営責任者ウェブサイト
201553Julie Eastlandwww.harpoontx.com

Harpoon Therapeutics, Inc. 基礎のまとめ

Harpoon Therapeutics の収益と売上を時価総額と比較するとどうか。
HARP 基礎統計学
時価総額US$492.35m
収益(TTM)-US$30.50m
売上高(TTM)US$37.34m

13.2x

P/Sレシオ

-16.1x

PER(株価収益率

収益と収入

最新の決算報告書(TTM)に基づく主な収益性統計
HARP 損益計算書(TTM)
収益US$37.34m
売上原価US$58.63m
売上総利益-US$21.29m
その他の費用US$9.21m
収益-US$30.50m

直近の収益報告

Sep 30, 2023

次回決算日

該当なし

一株当たり利益(EPS)-1.43
グロス・マージン-57.02%
純利益率-81.67%
有利子負債/自己資本比率194.4%

HARP の長期的なパフォーマンスは?

過去の実績と比較を見る